Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing buy-back program, with a total of 62,199 ordinary fully paid securities bought back on the previous day. This buy-back initiative reflects the company’s strategic efforts to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of therapies for neurodevelopmental disorders and neurodegenerative diseases. The company is known for its innovative approach to addressing unmet medical needs in these specialized areas.
YTD Price Performance: 11.04%
Average Trading Volume: 757,590
Technical Sentiment Signal: Buy
Current Market Cap: A$1.76B
For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue